A planned process is a processual entity that realizes a plan, which is the concretization of a plan specification (ID: ��obo:OBI_0000011��) . There are three basic types of planned processes KPT-330 FDA in OBI: biomaterial transformation, assay and Inhibitors,Modulators,Libraries data transformation, each of which is a process with three components: input, Inhibitors,Modulators,Libraries other participants and output, as illustrated in Figure 1. Figure 1 Planned Processes The biomaterial transformation process is defined as an event with one or more biomaterials as inputs and outputs. For example, DNA extraction from a blood sample is a biomaterial transformation process, where blood is the input biological material, DNA is the output material and the DNA extraction reagents and devices used in the process are other participants.
An assay is a planned process with the objective to produce information about some evaluant (ID: ��obo:OBI_0000070��) . It has biological Inhibitors,Modulators,Libraries material as input and data as output. For example, a microarray based genotyping assay has DNA as input and Inhibitors,Modulators,Libraries raw image data as output, where reagents, instruments and software utilized in the process are other participants. Starting with the raw data generated from the assay, we move to the data transformation processes. A data transformation process is a protocol application that produces output data from input data (ID: ��obo:OBI_0200000��) . With the application of OBI concepts in MIGen, genotyping procedure and data analysis components of a genotyping experiment are considered as a sequence of planned processes, each of which can be categorized as a biomaterial transformation, assay, or data transformation process.
With this abstractive view, virtually all steps executed in any genotyping experiment can be easily and explicitly specified at a high Inhibitors,Modulators,Libraries level, describing what information is required to be reported, without enumerating all the varieties for any given step. For example, MIGen specifies that if the input is a biomaterial, one must provide information on its type, its amount in value-unit pair, and other significant attributes. For detailed specification, please refer to the MIGen documentation. The application Dacomitinib of the OBI ontology within MIGen provides an abstractive framework that is generalized to define the necessary reporting standards for any process in a genotyping experiment. However, due to the complexity of genotyping experiments, there are many steps or processes involved, which can be reported at different levels of granularity depending on the experimenter��s definition of a process.